Certara, Inc. · NASDAQ:CERT
Certara — Technical Presentation (February 2022)
10 slides from Certara's technical presentation, Feb 24, 2022
Slide 1: What Oncology Drug Developers Should Expect from FDA's Project Optimus
What Oncology Drug Developers Should Expect from FDA’s Project Optimus February 24, 2022 David Wicks Vice President, Listing Services Nasdaq Julie M. Bullock, PharmD VP, Global Head Clinical Pharmacology & Translational Medicine Certara © Copyright 2022 Certara, L.P. All rights reserved.
Slide 2: Part 1: Maximum tolerated dose (MTD) as historical paradigm for oncology drug dosing
Part 1: Maximum tolerated dose (MTD) as historical paradigm for oncology drug dosing © Copyright 2022 Certara, L.P. All rights reserved.
Slide 3: Typical approach
Typical approach © Copyright 2022 Certara, L.P. All rights reserved.
Slide 4: Part 2: Project Optimus: What is it, and why now?
Part 2: Project Optimus: What is it, and why now? © Copyright 2022 Certara, L.P. All rights reserved.
Slide 5: What to expect
What to expect Maximum Tolerated Dose FDA Project Optimus © Copyright 2022 Certara, L.P. All rights reserved.
Slide 6: Friends of Cancer Research - Take-Home Messages
Friends of Cancer Research - Take-Home Messages © Copyright 2022 Certara, L.P. All rights reserved.
Slide 7: Part 3: How to get ready for Project Optimus
Part 3: How to get ready for Project Optimus © Copyright 2022 Certara, L.P. All rights reserved.
Slide 8: Friends of Cancer Research – Expectations for Dose-Finding
Friends of Cancer Research – Expectations for Dose-Finding • Establishing a therapeutic window based on activity and toxicity is ‘integral’ • Use preclinical data to define target saturation to narrow the range of doses for further clinical evaluation • Well-defined biomarkers can support understand
Slide 9: What is Bracketing?
What is Bracketing? © Copyright 2022 Certara, L.P. All rights reserved.
Slide 10: FoCR - Dose-Finding Trial Design Considerations
FoCR - Dose-Finding Trial Design Considerations • Randomized, compare at least 2 dose levels • Sufficiently sized to understand general shape of dose/exposure-activity/toxicity relationships (i.e., not powered) • Identify the minimally active dose Trial • Extended follow up - long-term characterizat